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Polymicrogyria is a malformation of cortical development. The aetiology of polymicrogyria remains poorly understood. Using
whole-exome sequencing we found de novo heterozygous missense GRIN1 mutations in 2 of 57 parent-offspring trios with
polymicrogyria. We found nine further de novo missense GRIN1 mutations in additional cortical malformation patients. Shared
features in the patients were extensive bilateral polymicrogyria associated with severe developmental delay, postnatal microcephaly,
cortical visual impairment and intractable epilepsy. GRIN1 encodes GluN1, the essential subunit of the N-methyl-D-aspartate
receptor. The polymicrogyria-associated GRIN1 mutations tended to cluster in the S2 region (part of the ligand-binding
domain of GluN1) or the adjacent M3 helix. These regions are rarely mutated in the normal population or in GRIN1 patients
without polymicrogyria. Using two-electrode and whole-cell voltage-clamp analysis, we showed that the polymicrogyria-associated
GRIN1 mutations signiﬁcantly alter the in vitro activity of the receptor. Three of the mutations increased agonist potency while
one reduced proton inhibition of the receptor. These results are striking because previous GRIN1 mutations have generally caused
loss of function, and because N-methyl-D-aspartate receptor agonists have been used for many years to generate animal models of
polymicrogyria. Overall, our results expand the phenotypic spectrum associated with GRIN1 mutations and highlight the import-
ant role of N-methyl-D-aspartate receptor signalling in the pathogenesis of polymicrogyria.
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Introduction
Malformations of cortical development (MCDs) are a spec-
trum of brain abnormalities that occur due to disruption of
the intricate developmental processes that form the cerebral
cortex. Although rare, MCDs have a major impact on the
lives of patients and their families. Polymicrogyria is a subtype
of MCD characterized, macroscopically, by an excessive
number of small cortical folds (gyri). At a microscopic level,
polymicrogyria is associated with abnormal cortical architec-
ture including thinning or loss of cortical layers (Squier and
Jansen, 2014; Jansen et al., 2016). The clinical effects of poly-
microgyria depend on the extent and regions of the brain
affected. Common consequences include intellectual disability,
epilepsy, spasticity and cortical visual impairment (Stutterd
and Leventer, 2014). Polymicrogyria can result from non-gen-
etic events such as hypoxic-ischaemic insults or congenital in-
fections. In addition, a range of chromosomal and single-gene
disorders have been identiﬁed in polymicrogyria patients
(Jansen and Andermann, 2005; Stutterd and Leventer,
2014). Despite these discoveries, the underlying cause of the
malformation remains unknown in the majority of patients.
Polymicrogyria is usually a sporadic disorder, with most
patients having no family history. Polymicrogyria also
causes a signiﬁcant loss of reproductive ﬁtness. This sug-
gests a role for de novo mutations in the aetiology of the
disorder. Recent candidate gene and exome sequencing stu-
dies have shown that de novo mutations cause polymicro-
gyria in some patients (Jaglin et al., 2009; Riviere et al.,
2012; Mirzaa et al., 2014). Based on these observations we
took the approach of exome sequencing in a cohort of 57
parent-offspring trios. This strategy led us to identify two
likely causal variants in GRIN1 in patients with extensive
bilateral polymicrogyria. GRIN1 encodes GluN1, the ob-
ligatory subunit of the N-methyl-D-aspartate (NMDA) re-
ceptor, an ionotropic glutamate receptor that is highly
expressed in the foetal brain (Law et al., 2003).
Mutations in GRIN2B, a gene that encodes a different
NMDA receptor subunit, have recently been reported in
MCD patients (Platzer et al., 2017). Therefore, having
observed two de novo GRIN1 mutations in patients with
polymicrogyria, we searched for additional GRIN1 muta-
tions in MCD patients. Furthermore, we examined the
functional impact of polymicrogyria-associated GRIN1
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mutations by computer-based protein structure modelling
and in vitro electrophysiological analysis.
Materials and methods
Patients
Patients 1 and 2 were part of a cohort of 57 unrelated pro-
band-parent trios recruited from Clinical Genetic and
Paediatric Neurology clinics around the UK. All probands
had polymicrogyria demonstrated by MRI and conﬁrmed by
review of the neuroradiology. The probands had no known
cause for their polymicrogyria and normal array comparative
genome hybridization. Parents were judged to be unaffected
based on history and a brief physical examination. Most par-
ents had not undergone brain imaging. For more details about
the UK cohort see Supplementary Table 1. The study was
approved by the Research Ethics Committee for Wales
(09/MRE09/51). Informed consent was obtained from all par-
ticipants (or their parents/legal guardians) prior to testing.
Patients 3, 4, and 6–11 were ascertained through a request
to collaborators and members of the European Network on
Brain malformations looking for similar patients. Patients 3
and 4 underwent trio-based whole exome sequencing as part
of an ongoing research program in France. Patients 6–8 had
trio-based exome sequencing performed during their clinical
diagnostic workup. Patients 9–11 were part of a cohort of
211 polymicrogyria patients who underwent targeted sequen-
cing of the GRIN1 gene as part of a US-based research pro-
gram. Patient 5 had trio-based whole exome sequencing
performed on a clinical basis. He was ascertained due to ap-
pearing in a poster at the European Paediatric Neurology
Society Congress 2015.
Exome sequencing and in silico
prediction
Standard approaches to exome sequencing and variant ﬁltering
were used. Detailed descriptions are given in the
Supplementary material. Predictions of the functional impact
of the de novo mutations were made by a range of analysis
programs. These included PhyloP (Pollard et al., 2010), SIFT
(Kumar et al., 2009), PolyPhen-2 (Adzhubei et al., 2010),
MutationTaster (Schwarz et al., 2014), CADD v1.3 (Kircher
et al., 2014) and M-CAP (Jagadeesh et al., 2016). We searched
the ExAC database for each variant (release 0.3, 14 January
2016) (Lek et al., 2016). Genomic coordinates are based on
genome build hg19/GRCh37 (February 2009). Coding and
protein positions of the GRIN1 mutations are based on
GenBank accession codes NM_007327.3 (ENST00000371
561.3) and NP_015566.1 respectively.
Homology modelling
Structural modelling of wild-type and mutant GluN1, and
wild-type GluN2A proteins was carried out using a previ-
ously-described homology-based modelling pipeline (Mullins,
2012). This approach uses the solved structure of a homolo-
gous template to model the native folds of a target sequence.
The target sequences selected were wild-type GluN1 (based on
Q05586, Uniprot Isoform 3 FASTA ﬁle) and wild-type
GluN2A (based on Q12879, Uniprot Isoform 1 FASTA ﬁle).
The template for both Q05568 and Q12879 was the crystal
structure of the GluN1a/GluN2B NMDA receptor (4PE5 chain
A) from Rattus norvegicus (Karakas and Furukawa, 2014).
The 4PE5 chain A contains the amino terminal domain, agon-
ist binding domain, and transmembrane domain of the wild-
type channel tetramer. We constructed our models using two
GluN1 and two GluN2A subunits arranged as 1-2-1-2. Target
and template underwent structural and consensus alignment
using T-Coffee (Notredame et al., 2000). Homology modelling
was performed by MODELLER (Webb and Sali, 2016). The
putative structure was reﬁned to improve the accuracy of
non-conserved regions, optimize bond geometries and remove
unfavourable contacts. Structural models were viewed and
analysed using the UCSF Chimera software (https://www.cgl.
ucsf.edu/chimera/) (Pettersen et al., 2004). Each mutant recep-
tor was superimposed onto the wild-type model. The effects on
the transmembrane helices were assessed by measuring the dis-
placement, between the two models, of residues at the ends of
each helix (from alpha carbon atoms). The residues were 559,
581, 615, 606, 655, 630, 810 and 828. The superimposed
models were also used to calculate root-mean-square deviation
(RMSD) values for nine domains (using all backbone atoms in
the speciﬁed residues): amino terminal (residues 23–394), ﬁrst
and second ligand binding domains (S1 and S2; residues
395–544 and 658–808, respectively), transmembrane domains
one to four (M1–M4; residues 560–580, 606–615, 637–657,
and 813–833), DRPEER motif (658–663) and SYTANLAAF
motif (646–654). UCSF Chimera FindHBond function
(using the default relaxation) was used to predict hydrogen
bonding between the glycine ligand and the glycine-binding
residues of GluN1. UniProt lists these as 516–518, 523, 688
and 732.
Expression plasmids and mutagenesis
For two-electrode voltage clamp recordings, the cDNA for
human wild-type NMDA subunits GluN1, GluN2A, and
GluN2B (GenBank accession codes: NP_015566, NP_000824
and NP_000825, respectively) were subcloned into pCI-neo
(Hedegaard et al., 2012). Mutant GluN1-Y647C, GluN1-
R659T, GluN1-N674I, GluN1-D789N and GluN1-R794Q
were generated by site-directed mutagenesis using the
QuikChange
TM
protocol with Pfu DNA polymerase (Agilent
Technologies). The parental strand was replicated with the
desired mismatch incorporated into the primer (Yuan et al.,
2005). Methylated parental DNA template was digested with
Dpn I. The nicked double-stranded mutant DNA was trans-
formed into TOP10 Competent Cells (Life Technologies). The
mutations were veriﬁed by sequencing through the region of
the mutations. For whole-cell voltage clamp recordings the
cDNA for human wild-type GRIN1 and GRIN2B (Myc-
DDK-tagged, based on GenBank accession codes NM_00
7327 and NM_000834, respectively) were subcloned into
pCMV6-Entry (OriGene Technologies, catalogue numbers
RC216458 and RC223623). Mutant GluN1-N674I was gen-
erated in pCMV6-GluN1 by site-directed mutagenesis using
the QuikChange
TM
mutagenesis kit as described above and ver-
iﬁed by Sanger sequencing.
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Two-electrode voltage clamp
recordings
Two-electrode voltage clamp recordings were performed as
previously described (Hansen et al., 2013; Yuan et al., 2014;
Chen et al., 2017b). Brieﬂy, coding RNA for wild-type and
mutant GluN1 was synthesized in vitro from linearized tem-
plate cDNA and injected into Xenopus laevis oocytes
(Ecocyte). Following injection, the oocytes were stored at
15–19C in Barth’s solution containing (in mM) 88 NaCl,
2.4 NaHCO3, 1 KCl, 0.33 Ca(NO3)2, 0.41 CaCl2, 0.82
MgSO4 and 5 Tris/HCl (pH 7.4 with NaOH). Voltage-clamp
recordings were performed 2–4 days post-injection at room
temperature (23C). The recording solution contained (in
mM) 90 NaCl, 1 KCl, 10 HEPES, 0.5 BaCl2 and 0.01
EDTA (pH 7.4 with NaOH). Voltage and current electrodes
were ﬁlled with 0.3 and 3.0M KCl, respectively, and current
responses were recorded at a holding potential of 40mV
(unless otherwise stated). Data acquisition and voltage control
were accomplished with a two-electrode voltage-clamp ampli-
ﬁer (OC725, Warner Instrument). NMDA receptor agonists
(glutamate or glycine) and antagonists (Mg2+ or H+ ) were
applied to the oocyte using a computer-controlled eight-modu-
lar valve positioner (Digital MVP Valve, Hamilton). Glutamate
(100mM) and glycine (100mM) were used in all oocyte experi-
ments unless otherwise stated. The agonist concentration-re-
sponse curves were ﬁtted with:
Response %ð Þ ¼ 100= 1þ EC50= agonist½ ð ÞnH
  ð1Þ
where EC50 is the agonist concentration that elicited a half-
maximal response and nH is the Hill slope. IC50 values for
Mg2+ were obtained by ﬁtting the concentration-response data
with:
Response %ð Þ ¼ 100minimumð Þ=
1þ modulator½ =IC50ð ÞnH
 
þminimum
ð2Þ
where IC50 is the concentration that produces a half-maximal
effect, and minimum is the degree of residual inhibition at a
saturating concentration of Mg2+ . Data were expressed as
mean  standard error of the mean (SEM).
Preparation and transfection of HEK
293 cells
HEK 293 cells (ATCC) were plated onto glass coverslips
coated in 100mg/ml poly-D-lysine and incubated at 37C
(5% CO2 in DMEM/F12 1:1 media) supplemented with
10% foetal bovine serum, 2mM glutamine, 50 U/ml penicillin
and 50 mg/ml streptomycin. The cells were co-transfected with
plasmid cDNAs encoding green ﬂuorescent protein (GFP),
GluN2B, and GluN1 or GluN1–N674I. For transfection,
media was changed to S-MEM media with 1% foetal bovine
serum, 0.5mM glutamine and 0.5mM CaCl2. Mixed pCMV
plasmid DNA (0.25 mg each of GluN2B, GluN1 or GluN1-
N674I, and 0.125 mg nucGFP) with 50 ml Opti-MEM
TM
and
1 ml Lipofectamine
TM
2000 (Life Technologies) was added to
each well and the mixture incubated at 37C for 4 h. Media
was then changed to transfection media plus 100mM D-AP5
(R&D systems), a competitive NMDA receptor antagonist.
The cells were inspected by ﬂuorescence microscope 16–24 h
post-transfection. Cells expressing GFP were used for whole-
cell voltage-clamp recordings.
Whole-cell voltage clamp recordings
Whole-cell voltage clamp recordings were performed as previ-
ously described (Jiang et al., 2005; Thompson et al., 2012).
Membrane potential of transfected cells were held at 60mV
(at room temperature, 23C) using a patch clamp ampliﬁer
(EPC10, HEKA). Borosilicate glass microelectrodes, 5–5.5M
were ﬁlled with intracellular solution containing (in mM) 117
KCl, 10 NaCl, 11 HEPES, 11 EGTA, 2 MgCl2, 1 CaCl2, 2
Na2ATP (pH 7.2 with KOH). The extracellular solution con-
tained (in mM) 135 NaCl, 5 KCl, 5 HEPES, 10 glucose, 1.2
MgCl2 and 1.25 CaCl2 (pH 7.4 with NaOH). Solution ex-
change was achieved with a rapid solution changer (BioLogic)
and data collected using PatchMaster software (HEKA). Peak
currents were deﬁned as the maximal amplitude of response
during the agonist application; responses were plotted as cur-
rent density (pA/pF). Concentration-response curves were con-
structed and ﬁtted by Equation 1 using Prism 7.
Results
GRIN1 mutations in patients with
polymicrogyria
We performed whole-exome sequencing in 57 unrelated
individuals with polymicrogyria and their unaffected par-
ents. Two of the polymicrogyria patients (Patients 1 and 2)
had de novo missense mutations in GRIN1 [c.2021A4T,
p.(Asn674Ile) and c.2381G4A, p.(Arg794Gln)]. Apart
from known polymicrogyria genes, GRIN1 was the only
gene with de novo mutations in more than one patient. (A
manuscript describing all de novo mutations in the cohort
is in preparation). Given the predicted rate of de novo
missense mutations in GRIN1 (from ExAC: 4.4  105)
the observation of more than one de novo GRIN1 missense
mutation in 57 subjects has a P-value of 3.1  106 (bino-
mial test). This is close to a strict Bonferroni-corrected ex-
periment-wide P-value threshold of 2.5  106 per gene
(Kiezun et al., 2012). We found nine further GRIN1 mis-
sense mutations in additional MCD patients (Table 1). The
11 missense mutations were all de novo, affected highly-
conserved residues (Supplementary Fig. 1) and in silico pre-
dictions suggested they were all deleterious (Supplementary
Table 2). Two of the mutations [c.1975C4T,
p.(Arg659Trp) and c.2365G4A, p.(Asp789Asn)] were re-
current. Shared clinical features in the live-born patients
were severe or profound developmental delay, postnatal
microcephaly, cortical visual impairment and treatment-re-
sistant epilepsy. A summary of the clinical features is given
in Table 1 (detailed case reports are provided in the
Supplementary material). Some previous GRIN1 patients
have been noted to have abnormal eye movements resem-
bling oculogyric crises and stereotypic hand movements. At
least four of our series had similar features (abnormal
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movements in Patient 4, stereotypic movements in Patient 6,
and episodes of gaze deviation in Patients 8 and 10).
Abnormal movements may have been present in the other
patients but either unreported or misinterpreted (e.g. as seiz-
ures or roving eye movements). Magnetic resonance images
from all subjects (apart from Patients 3 and 7) were available
for review (Fig. 1). The patients demonstrated an extensive
bilateral cortical malformation similar in appearance to tubu-
linopathy- or GRIN2B-associated dysgyria (Platzer et al.,
2017). None of the brains have been examined histologically
but the magnetic resonance appearance was most consistent
with polymicrogyria. The distribution of the polymicrogyria
was typically diffuse (frontal, perisylvian, parietal and tem-
poral) and bilateral but with some occipital sparing. Patients
8 and 9 had polymicrogyria in the frontal and parietal re-
gions but the extent of perisylvian involvement was unclear
from the available images. Patient 6 had predominantly
perisylvian polymicrogyria with some frontal, parietal and
temporal involvement (grade 2 bilateral perisylvian polymi-
crogyria). This milder cortical malformation correlated with
the patient’s milder phenotype (sitting and walking, but still
severely delayed). Additional magnetic resonance ﬁndings in
the patients were increased extra-axial spaces (particularly
anteriorly, 9/11), enlarged lateral ventricles (8/11), reduced
white matter volume (9/11), thinning of the corpus callosum
(4/11) and abnormal hippocampi (3/11).
Lemke et al. (2016) reviewed the MRI ﬁndings of 19
previous GRIN1 patients. None were noted to have poly-
microgyria (delayed formation of sulci was observed in
one patient with homozygous GRIN1 nonsense muta-
tions) (Lemke et al., 2016). To ensure our ﬁndings were
not simply due to differences in the interpretation of radi-
ology we reviewed MRI brain images from four previous
non-polymicrogyria patients with GRIN1 mutations
(p.Asp552Glu, p.Met641Ile, p.Gly815Arg and
p.Gly827Arg) (Ohba et al., 2015; Lemke et al., 2016).
This conﬁrmed the absence of polymicrogyria.
Clustering of polymicrogyria-
associated GRIN1 mutations
We compared the positions of the 11 polymicrogyria-asso-
ciated GRIN1 mutations with 16 different heterozygous
proven (or likely) de novo GRIN1 mutations previously
reported in 23 patients with non-syndromic intellectual dis-
ability and epileptic encephalopathy (Fig. 2) (Lemke et al.,
2016). We observed that most polymicrogyria-associated
mutations occurred in the S2 domain of GluN1 or the ad-
jacent M3 helix. The proportion of mutation in these two
domains (9/11) was greater than expected based on the
distribution of previous GRIN1 mutations (5/23;
P = 0.002, Fisher’s exact test). Furthermore, no polymicro-
gyria-associated mutations were observed in M4, a domain
where nearly half of all previous mutations were located.
Six polymicrogyria-associated GRIN1 mutations
[p.Arg659Trp (two mutations), p.Asn674Ile, p.Asp789Asn
(two mutations) and p.Arg794Gln] were located in the S2
domain. The S2 domain forms part of the ligand-binding
domain of GluN1 and has been shown to be highly intoler-
ant to variation (Ogden et al., 2017). The recurrent
p.Arg659Trp mutation is in the DRPEER motif of S2 (resi-
dues 658–663). This motif is close to the extracellular end
of M3, near the channel pore entrance. Only two previous
GRIN1 mutations have been located in S2 (p.Glu662Lys
and p.Ser688Tyr) (Hamdan et al., 2011; Zehavi et al.,
2017). Neither patient was reported to have polymicrogyria
although the p.Glu662Lys patient only had a CT brain
scan (MRI was not done) (Hamdan et al., 2011). CT gen-
erally lacks the resolution to detect polymicrogyria.
Three polymicrogyria-associated GRIN1 mutations
(p.Tyr647Cys, Asn650Ile and p.Ala653Gly) were in close
proximity to the S2 domain in a region of highly-conserved
residues at the extracellular end of M3. These residues
(646–654) are known as the Lurcher motif
(SYTANLAAF). This motif is thought to act as the major
permeation barrier at the intersection of four M3 helices
(Murthy et al., 2012). Different mutations affecting resi-
dues 647 and 650 have previously been reported in patients
with epileptic encephalopathy (Epi4K Consortium et al.,
2013; Ohba et al., 2015). Neither was reported to have
polymicrogyria although the p.Tyr647Ser patient only
had a CT brain scan. The ﬁnal two polymicrogyria-asso-
ciated mutations (p.Leu551Pro and p.Ser553Leu) were
located in the S1-M1 linker region. The tertiary structure
of GluN1 means the residues are located close to the extra-
cellular end of the M3 helix (Fig. 2). It has recently been
proposed that the pre-M1 region is close enough to M3 to
interact as a key gating element (Sobolevsky et al., 2009;
Chen et al., 2017b; Ogden et al., 2017).
Modelling the structural effects of
GRIN1 mutations
We hypothesized that polymicrogyria-associated and previ-
ous GRIN1 mutations might have different effects on the
structure of GluN1. To study this we developed a 3D
model of the GluN1/GluN2A NMDA receptor based on
the rat GluN1/GluN2B tetramer (Fig. 2). We simulated
models for the nine polymicrogyria-associated GRIN1 mu-
tations and 16 previous GRIN1 mutations. We measured
each mutant model in three ways: (i) the displacement, be-
tween mutant and wild-type, of the extracellular and intra-
cellular ends of each transmembrane helix; (ii) the
displacement, between the mutant and wild-type, of nine
key domains. A RMSD value (a measure of average dis-
tance between the two superimposed structures) was calcu-
lated for each domain; and (iii) the number of hydrogen
bonds between the glycine ligand and the glycine-binding
residues of GluN1.
Analysis of transmembrane helix positions (Supplementary
Table 3) and domain-speciﬁc RMSD values (Supplementary
Table 4) revealed no consistent differences between previous
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Figure 1 Polymicrogyria in patients with GRIN1 mutations. Axial, midline sagittal and coronal brain magnetic resonance images for
Patient 1 at age 2 months (A–C) and Patient 2 at age 5 months (D–F); axial magnetic resonance images for Patient 4 at age 3 months (G), Patient
5 at age 6 weeks (H) and Patient 6 at age 8 months (I); axial, sagittal and coronal images for Patient 8 at age 3 months (J–L); a coronal image for
Patient 9 at age 4 months (M); axial images from Patient 10 at age 8 months (N) and Patient 11 at age 2 months (O). Images B, C and K are T1-
weighted. All other images are T2-weighted. The images demonstrate bilateral extensive polymicrogyria (white arrows) more severe anteriorly.
Note the increased extra-axial spaces and enlarged lateral ventricles (in most images apart from I) suggesting cerebral volume loss.
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and polymicrogyria-associated GRIN1 mutations. The re-
gions of GluN1 most affected by GRIN1 mutations in
both groups were M2, M3 (particularly the extracellular
end) and S2. All GRIN1 mutants had RMSD values 42 A˚
for the S2 domain and DRPEER motif. The extracellular end
of the M3 helix (the part of the helix involved in the channel
pore entrance) was displaced 41 A˚ for all GRIN1 mutants
apart from polymicrogyria-associated p.Asp789Asn (0.67 A˚).
The p.Asp789Asn mutation stood out from other mutations
in causing the least displacement of transmembrane helices
(all 41.01 A˚) and the lowest RMSD value for the M3 helix
(1.17 A˚). The p.Asp789Asn mutation still had its greatest
effects on the S2 domain (RMSD 3.06 A˚) where it was
located. The polymicrogyria-associated p.Leu551Pro and
p.Ser553Leu mutations were located in the S1-M1 linker
region but had their greatest effects on the RMSD values
of the M2, M3 and S2 domains. On average polymicro-
gyria-associated mutations generated slightly more hydrogen
bonds with glycine (6.8) compared with previous mutations
(4.8; P = 0.02, Mann-Whitney U-test) and wild-type (4)
(Table 2). However, the effects varied between mutations.
All polymicrogyria-associated mutations increased the
number of hydrogen bonds with glycine apart from
p.Asp789Asn, which formed one less than wild-type.
Impact of GRIN1 mutations on
NMDA receptor function
To investigate whether polymicrogyria-associated GRIN1
mutations inﬂuence NMDA receptor function in vitro we
Figure 2 Position of the GRIN1 mutations. (A) This ribbon diagram of the GluN1 subunit of the NMDA receptor demonstrates the
location of the binding site of glycine in the ligand binding domain, transmembrane helices (M1-M4 in green) and glycine binding residues of GluN1
(orange residues and blue underlined numbers). Mutated residues are in yellow. Polymicrogyria-associated mutations are in red text and previous
GRIN1 mutations are in black text. (B) The same ribbon model rotated 90 degrees in the axial plane. (C) A model of the C-terminal end of GRIN1.
In addition to showing M1-M4, the model shows the position of the second ligand binding domain (S2), calmodulin biding domain (CBD) and the
C-terminal domain (CTD). Codon position is listed below the model. Heterozygous GRIN1 variants reported or reviewed by Lemke et al. (2016)
(non-polymicrogyria, white triangles) are shown above the model. The two yellow triangles represent subjects with CT brain imaging only.
Polymicrogyria-associated GRIN1 mutations (red triangles) cluster in the S2 domain (6/11) or in the adjacent Lurcher motif of M3 (3/11).
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undertook site-directed mutagenesis to introduce ﬁve
of the GRIN1 mutations (p.Tyr647Cys, p.Arg659Trp,
p.Asn674Ile, p.Asp789Asn and p.Arg794Gln) into cDNA
encoding human GluN1. We then expressed wild-type and
mutant GluN1 with either human wild-type GluN2A or
GluN2B in Xenopus oocytes and evaluated the effects of
these mutants on pharmacological properties of NMDA
receptors by using two-electrode voltage clamp recordings,
including agonist potency (glutamate and glycine), as well
as magnesium and proton sensitivity. The concentration
that produced a half-maximal current response (EC50)
was determined by measuring the current response to a
range of glutamate (in the presence of 100 mM glycine)
and glycine (in the presence of 100mM glutamate) concen-
trations at a holding potential of 40mV. The magnesium
sensitivity (IC50) was determined by measuring the effect of
different magnesium concentrations on agonist-evoked cur-
rents (by 100mM glutamate and 100mM glycine) at a hold-
ing potential of 60mV. The proton sensitivity was
evaluated as the percentage of receptor activity at pH 6.8
compared with receptor activity at pH 7.6 (holding poten-
tial of 40mV).
The p.Arg659Trp and p.Arg794Gln mutations had simi-
lar effects; both increased the potency (reduced EC50
values) of agonists, and in particular, glutamate. The
EC50 of mutant receptors was reduced to 10–20% of
wild-type levels (Table 3). The potency of glycine was
also increased: EC50 was 71% of wild-type for GluN1-
R794Q/GluN2A, 61% for GluN1-R794Q/GluN2B, 36%
for GluN1-R659W/GluN2A and 15% for GluN1-
R659W/GluN2B. There were no detectable differences in
Mg2+ blockade. Proton inhibition was not statistically sig-
niﬁcant apart from a reduced block in GluN1-R659W/
GluN2A (70% mutant versus 52% wild-type).
The p.Tyr647Cys mutation demonstrated a profound
increase in the potency of glutamate with an EC50 of just
1.6% of wild-type for GluN1-Y647C/GluN2A and
2.4% for GluN1-Y647C/GluN2B. There was a similarly
increased sensitivity to glycine (EC50 4.6% for GluN1-
Y647C/GluN2A; 11.2% for GluN1-Y647C/GluN2B).
There was a statistically signiﬁcant increase in Mg2+ block-
ade for GluN1-Y647C/GluN2A (IC50 38% of wild-type)
but not GluN1-Y647C/GluN2B (IC50 81% of wild-type)
(Table 3). There were also signiﬁcant but variable effects
on proton inhibition: slightly increased in GluN1-Y647C/
GluN2A (35% mutant versus 41% wild-type) but reduced
in GluN1-Y647C/GluN2B (30% mutant versus 15%
wild-type).
Table 2 Effect of GRIN1mutations on hydrogen bonds between the glycine ligand and the glycine-binding residues of
GluN1
GluN1 residue Pro516 Thr518 Arg523 Ser687 Ser688 Asp732 Bond
total
Wild-type       4
Previous GRIN1 mutations
S549R       5
D552E       4
P557R       3
S560dup      (689)  (733) 4
G618R       3
G620R       5
M641I       8
A645S       4
Y647S       5
N650K       3
E662K       4
G815R       5
G815V       8
F817L       3
G827R       6
R844C       6
Polymicrogyria-associated GRIN1 mutations
L551P       9
S553L       6
Y647C       6
N650I       7
A653G       9
R659W       6
N674I       10
D789N       3
R794Q       5
Number of hydrogen bonds between glycine and specified residues:  (none),  (one),  (two),  (three). All predicted hydrogen bonds were 53 A˚ in length.
De novo GRIN1 mutations in polymicrogyria BRAIN 2018: Page 9 of 15 | 9
Downloaded from https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awx358/4818912
by Public Health Wales NHS Trust user
on 22 January 2018
The p.Asn674Ile mutant had a different proﬁle of effects.
The EC50 for glycine was unchanged for GluN1-N674I/
GluN2A but increased to 226% for GluN1-N674I/
GluN2B (Table 3 and Fig. 3A). This indicated a reduced
potency for glycine. The EC50 of glutamate was not signiﬁ-
cantly altered for GluN1-N674I/GluN2A or GluN1-N674I/
GluN2B (Table 3 and Fig. 3B). However, p.Asn674Ile did
demonstrate signiﬁcantly reduced proton inhibition (72%
GluN1-N674I/GluN2A versus 48% wild-type GluN1/
GluN2A; 50% GluN1-N674I/GluN2B versus 16% wild-
type GluN1/GluN2B). There was no signiﬁcant difference
in Mg2+ blockade for p.Asn674Ile receptors. To conﬁrm
that p.Asn674Ile reduced glycine potency we assessed the
mutation in a second, separate in vitro heterologous expres-
sion setting. We co-expressed wild-type and mutant GluN1
with human GluN2B in HEK 293 cells and evaluated the
concentration-effect curves for agonist (NMDA) and co-
agonist (glycine) using whole-cell voltage clamp. The
whole-cell voltage clamp results (Fig. 3C and D) were con-
sistent with the two-electrode voltage clamp ﬁndings and
demonstrated a pronounced loss of sensitivity to glycine
(EC50 310% of wild-type; GluN1-N674I/Glu2B: 0.93 mM,
n = 8; versus wild-type GluN1/Glu2B: 0.30mM, n = 8;
P50.0001; unpaired t-test) and a moderate reduction in
the potency of NMDA (EC50 164% of wild-type; GluN1-
N674I/Glu2B: 19.71 mM, n = 6; versus wild-type GluN1/
Glu2B: 12.05 mM, n = 8; P = 0.01; unpaired t-test).
Multiple attempts (mutagenesis, RNA syntheses, RNA
injection, and recordings) were made to express
p.Asp789Asn mutant receptors (as both GluN1/GluN2A
and GluN1/GluN2B) in Xenopus oocytes. The current
amplitudes at saturating agonist concentrations (up to
1mM glutamate and 3mM glycine at holding potential
of 40mV) were too small to characterize the effects on
NMDA receptor pharmacological properties (GluN1-
D789N/Glu2A: 13  2.8 nA, n = 14; versus wild-type
GluN1/Glu2A: 855  199 nA, n = 14; GluN1-D789N/
Glu2B: 11  3.1 nA, n = 14; versus wild-type GluN1/
Glu2B: 585  156 nA, n = 14). We therefore evaluated
the expression levels of GluN1-D789N using a b-lactamase
activity assay in transiently-transfected HEK cells
(Supplementary material) (Swanger et al., 2016). The
ratio of surface-to-total protein levels for the mutant
GluN1-D789N was reduced to 71  4.2 % (n = 4;
P = 0.04; unpaired t-test) of wild-type when co-expressed
with wild-type GluN2A, and had no signiﬁcant change
(115  46 %; n = 8; P = 0.46; unpaired t-test) when co-ex-
pressed with wild-type GluN2B (Supplementary Fig. 2),
suggesting that the complete loss of current responses for
GluN1-D789N is not due to a trafﬁcking defect or lack of
surface expression but rather a functional change in the
membrane-bound receptor.
Discussion
By using exome data from parent-offspring trios we identi-
ﬁed 2 of 57 polymicrogyria patients with de novo missense
mutations in GRIN1. Another nine de novo missense
GRIN1 mutations were identiﬁed in additional MCD pa-
tients. Shared features in the patients were extensive bilat-
eral polymicrogyria, severe or profound developmental
delay, postnatal microcephaly, cortical visual impairment
and treatment-resistant epilepsy. De novo missense muta-
tions in GRIN1 have previously been reported in patients
with non-syndromic intellectual disability (Hamdan et al.,
Table 3 Summary of two-electrode voltage clamp data
Constructs Glu EC50,
mM (n)
Mutant/
WT, %
Gly EC50,
mM (n)
Mutant/
WT, %
Mg2+ IC50,
mM (n)
Mutant/
WT, %
%,
pH 6.8/
pH 7.6
%,
Mutant/
WT
WT GluN1/GluN2A 3.3  0.04 (6) 1.3  0.05 (6) 24  5.9 (5) 51  1.7 (6)
GluN1-R794Q/GluN2A 0.68  0.06 (6)* 21 0.92  0.09 (6)* 71 31  5.4 (6) 129 47  0.9 (6) 92
WT GluN1/GluN2B 1.7  0.12 (7) 0.33  0.05 (6) 18  0.53 (6) 16  0.6 (5)
GluN1-R794Q//GluN2B 0.21  0.03 (14)* 12 0.20  0.02 (12)* 61 17  1.7 (7) 94 17  1.0 (7) 106
WT GluN1/GluN2A 3.2  0.04 (6) 1.3  0.01 (7) 24  5.9 (5) 48  6.4 (5)
GluN1-N674I/GluN2A 2.2  0.14 (6) 69 1.6  0.08 (6) 123 34  5.3 (6) 142 72  3.2 (6)* 150
WT GluN1/GluN2B 1.5  0.17 (10) 0.38  0.06 (6) 26  3.7 (8) 16  0.9 (6)
GluN1-N674I/GluN2B 1.9  0.15 (14) 126 0.86  0.05 (11)* 226 24  2.6 (6) 92 50  1.3 (6)* 313
WT GluN1/GluN2A 3.9  0.28 (10) 1.0  0.11 (11) 29  4.1 (10) 52  1.1 (12)
GluN1-R659W/GluN2A 0.43  0.03 (18)* 11 0.36  0.09 (10)* 36 37  3.5 (7) 128 70  1.6 (11)* 135
WT GluN1/GluN2B 1.3  0.09 (9) 0.33  0.03 (12) 18  0.5 (6) 16  0.8 (10)
GluN1-R659W/GluN2B 0.25  0.04 (11)* 19 0.05  0.01 (14)* 15 20  3.4 (6) 111 15  1.7 (10) 94
WT GluN1/GluN2A 3.8  0.51 (6) 1.3  0.06 (9) 24  3.1 (6) 41  2.0 (6)
GluN1-Y647C/GluN2A 0.06  0.03 (5)* 1.6 0.06  0.01 (6)* 4.6 9.0  1.0 (5)* 38 35  2.1 (6)* 85
WT GluN1/GluN2B 1.7  0.08 (7) 0.41  0.05 (6) 21  3.1 (5) 15  2.5 (6)
GluN1-Y647C/GluN2B 0.04  0.01 (6)* 2.4 0.046  0.015 (9)* 11 17  4.3 (6) 81 30  3.5 (6)* 200
Data were from two-electrode voltage-clamp recordings on Xenopus oocytes at 40 mV holding potential (except for Mg2 + at 60 mV) and expressed as mean  SEM (n);
WT = wild-type; *P5 0.05, unpaired t-test, compared to the corresponding data from wild-type receptors recorded on the same day.
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2011; Redin et al., 2014; Zhu et al., 2015; Lemke et al.,
2016; Rossi et al., 2017), movement disorders (Ohba et al.,
2015; Chen et al., 2017a; Zehavi et al., 2017), epileptic
encephalopathy (Epi4K Consortium et al., 2013), and cere-
bral visual impairment (Bosch et al., 2016). The MRI fea-
tures seen in previous GRIN1 patients were non-speciﬁc
volume loss and generalized cerebral atrophy but not poly-
microgyria (Lemke et al., 2016). We note that at least two
previous GRIN1 patients only had CT brain scans, which
cannot reliably detect polymicrogyria. This raises the
possibility that some previous GRIN1 patients may have
had unrecognized polymicrogyria. It is also possible
that apparently non-polymicrogyria GRIN1 patients
(by MRI) may have subtle structural brain abnormalities
that are below the resolution of current scanning
technology.
The NMDA receptor is a tetrameric heteromultimer
that comprises two GluN1 subunits (encoded by GRIN1)
and two variable GluN2 subunits, which are encoded by
GRIN2A, GRIN2B, GRIN2C or GRIN2D. Like GluN1,
GluN2B is extensively expressed in the cerebral cor-
tex during foetal development (Liu et al., 2004). GRIN2B
mutations have been found in patients with autism
(O’Roak et al., 2011; Tarabeux et al., 2011), cerebral
visual impairment (Bosch et al., 2016), West syndrome
(Lemke et al., 2014) and intellectual disability (Endele
et al., 2010; Adams et al., 2014; Lemke et al., 2014; Hu
et al., 2016; Swanger et al., 2016). GRIN2B mutations
have also recently been observed in MCD patients
(Platzer et al., 2017). In contrast to the foetus, the main
GluN2 subunit of the adult brain is GluN2A. This change
occurs during early postnatal development and is thought
to be a key developmental switch (Liu et al., 2004).
GRIN2A mutations have been found in patients with epi-
lepsy-aphasia spectrum disorders (Carvill et al., 2013;
Lemke et al., 2013; Lesca et al., 2013; Gao et al., 2017),
early-onset epileptic encephalopathy (Endele et al., 2010;
Pierson et al., 2014; Yuan et al., 2014; Swanger et al.,
2016) and schizophrenia (Tarabeux et al., 2011).
However, consistent with its mainly postnatal expression,
GRIN2A mutations have not been reported to cause
MCDs.
The reason why some GRIN1 patients get polymicro-
gyria is uncertain. This may require additional factors in
the patient’s genetic background or environmental condi-
tions during gestation. Only two of our series were known
to have had testing for cytomegalovirus. Patient 5 had
negative postnatal serology. Patient 6 had positive testing
(urine PCR and serum IgM) at 4 months of age. However,
his mother had negative serology at 36 weeks, which sug-
gests the infection occurred postnatally. Other patients
were not tested because they lacked typical features of
Figure 3 The p.Asn674Ile mutation changes the response of the NMDA receptor to agonists. The top graphs display concentration-
response curves for (A) glycine (in the presence of 100 mM glutamate) and (B) glutamate (in the presence of 100 mM glycine) determined by two-
electrode voltage-clamp recordings from Xenopus oocytes expressing either wild-type (WT)-GluN1/GluN2B or GluN1-N674I /GluN2B. The
bottom graphs display concentration-response curves for (C) glycine (in the presence of 100 mM NMDA) and (D) NMDA (in the presence of
100 mM glycine) determined by whole-cell voltage-clamp recordings from transfected HEK 293 cells expressing either WT-GluN1/GluN2B or
GluN1-N674I /GluN2B. Error bars represent SEM.
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cytomegalovirus infection (e.g. rash, retinitis, brain calciﬁ-
cation or deafness). It has not been possible to retrospect-
ively screen the other patients for cytomegalovirus. We
observed that polymicrogyria-associated GRIN1 mutations
clustered in the S2 or M3 domains, regions that are signiﬁ-
cantly depleted of variation in control populations
(Swanger et al., 2016; Ogden et al., 2017). In addition,
the GluN1 S2 domain has rarely been mutated in non-
polymicrogyria GRIN1 patients. The GluN1 S2 domain
is critical to the binding of glycine, the co-agonist of the
NMDA receptor. Therefore, the observation of this puta-
tive genotype–phenotype correlation suggests that polymi-
crogyria and non-polymicrogyria mutations may have
different effects on co-agonist binding or the activation
state of the receptor. Inspecting the 3D model of GluN1
suggests the polymicrogyria-associated mutations in S2
reside close to the extracellular end of the M3 transmem-
brane helix that forms a bundle crossing that occludes ion
permeation. These variants may therefore alter gating. The
polymicrogyria-associated p.Arg659Trp mutation was
located in the DRPEER motif of S2. This motif is a
highly charged motif thought to inﬂuence the relative per-
meability of Ca2+ ions through the channel (Watanabe
et al., 2002). Similarly, the three M3 mutations
(p.Tyr647Cys, p.Asn650Ile and p.Ala653Gly) had milder
effects on the wider structure of the receptor but were
located in the highly-conserved Lurcher motif, which con-
trols NMDA receptor gating.
Our structural modelling found polymicrogyria-asso-
ciated mutations were associated with an increase in the
average number of hydrogen bonds between the glycine
ligand and the glycine-binding residues of GluN1. The for-
mation of additional hydrogen bonds may alter the kinetics
of co-agonist binding (e.g. increased afﬁnity). No other
stark differences between polymicrogyria-associated and
previous GRIN1 mutations were observed. The measure-
ments used (transmembrane helix position and domain-spe-
ciﬁc RMSD) may not have been sensitive to key differences
between the two groups. In addition, the structural model-
ling suggests there is heterogeneity in how polymicrogyria-
associated mutations affect GluN1 structure. This may have
confounded comparison between the two groups.
Two-electrode voltage clamp analysis showed that three
of the polymicrogyria-associated mutations (p.Tyr647Cys,
p.Arg659Trp and p.Arg794Gln) signiﬁcantly increased the
potency of both glutamate and glycine. This increased po-
tency may mean that mutant receptors can be activated at
lower concentrations of agonist than wild-type receptor.
Several lines of evidence link excess NMDA receptor sig-
nalling to polymicrogyria. The intracerebral injection of
ibotenate has been used for decades to generate in vivo
models of epilepsy and cortical malformations including
polymicrogyria (Marret et al., 1996; Takano et al.,
2004). Ibotenate is an agonist of both NMDA and gluta-
matergic metabotropic receptors. Intracerebral ibotenate in-
jection in newborn mice (Marret et al., 1995), hamsters
(Marret et al., 1996; Takano et al., 2004) and rats
(Takano and Matsui, 2015) causes a range of grey and
white matter changes, including polymicrogyria-like lesions,
similar to those seen following perinatal hypoxic/ischaemic
insults. Over-stimulation of NMDA receptors is thought to
lead to excitotoxicity due to excess calcium inﬂux through
the receptor channel (Choi et al., 1988; Zhou et al., 2013).
Profound gain-of-function NMDA receptor subunit muta-
tions are excitotoxic when expressed in vitro (Li et al.,
2016; Ogden et al., 2017). NMDA receptor-related excito-
toxicity has been implicated in hypoxic/ischaemic events
(Simon et al., 1984; Rothman and Olney, 1986).
Hypoxic/ischaemic events during foetal brain development
are a well-recognized cause of polymicrogyria in humans.
Calcium inﬂux through the NMDA receptor can lead to
activation of a range of cellular pathways including the
pro-survival PI3K-AKT pathway (Lafon-Cazal et al.,
2002; Wang et al., 2012). Activating mutations in compo-
nents of the PI3K-AKT pathway have been found in poly-
microgyria patients (Riviere et al., 2012; Mirzaa et al.,
2014). MCDs including polymicrogyria are a feature of
Zellweger syndrome, a rare metabolic disorder caused by
peroxisomal dysfunction. Analysis of a mouse model of
Zellweger syndrome showed that the neuronal migration
abnormalities seen in the mice were due to NMDA recep-
tor-mediated calcium mobilization (Gressens et al., 2000).
Another metabolic disorder associated with polymicrogyria
is glycine encephalopathy (Dobyns, 1989). The hyperglyci-
naemia in this condition may enhance the excitotoxic ac-
tivity of glutamate acting through the NMDA receptor
(Subramanian et al., 2015).
In contrast to the three potential gain-of-function poly-
microgyria-associated GRIN1 mutations, most previous
GRIN1 mutations caused dominant-negative effects result-
ing in a signiﬁcant loss of receptor function (Lemke et al.,
2016). Animal models suggest that NMDA receptor hypo-
function is less likely to disturb gross cortical structure.
Mice homozygous for GluN1 null alleles die soon after
birth from respiratory problems but do not have severe
abnormalities of neuronal migration (Messersmith et al.,
1997). Similarly, mice with a GluN1 deletion limited to
excitatory cortical neurons have only subtle disturbance
of cortical structure (Iwasato et al., 2000). However, a
simple model of gain-of-function GRIN1 mutations causing
polymicrogyria is challenged by the results for p.Asn674Ile.
Both two-electrode and whole-cell voltage clamp analyses
were consistent in showing this mutation decreased the po-
tency of glycine and possibly (to a lesser extent) glutamate.
How can we explain this apparently paradoxical ﬁnding?
There are a number of possible mechanisms that might
explain why p.Asn674Ile causes polymicrogyria.
First, the p.Asn674Ile mutation caused a signiﬁcant loss
of proton inhibition. GluN2B receptors are inhibited with
an IC50 at physiological pH. Therefore loss of proton in-
hibition will potentiate responses even at resting pH. This
may mean neurons are prone to excess calcium inﬂux, a
problem that will be exacerbated in low pH environments
(e.g. during oxidative stress). Recent work has shown the
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importance of the balance of signalling through synaptic
and extra-synaptic NMDA receptors (Zhou et al., 2015).
Activation of synaptic NMDA receptors activates pro-sur-
vival pathways. In contrast, massive and prolonged co-ac-
tivation of both synaptic and extrasynaptic receptors leads
to cell death. If p.Asn674Ile blunts the response of synaptic
receptors (e.g. through reduced agonist potency) while pro-
moting signalling at extrasynaptic receptors (e.g. through
reduced proton inhibition) this may tip the balance in
some neurons towards apoptosis. Alternatively, polymicro-
gyria may be a consequence of disturbed NMDA receptor
signalling regardless of whether there is gain- or loss-of-
function. There is evidence from in vitro studies that a
low-level background of NMDA activation is needed to
support neuronal survival (Zhou et al., 2015), guide
radial migration (Behar et al., 1999; Hirai et al., 1999)
and promote neuronal differentiation (Yoneyama et al.,
2008). Transient delivery of an NMDA antagonist to a
focal area of the cortex of newborn rats disturbs cortical
lamination and generates heterotopic cell clusters (Reiprich
et al., 2005). A range of NMDA antagonists, including
ethanol, have been shown to induce apoptosis in the
brains of developing rats (Olney et al., 2002). This is of
relevance as polymicrogyria has occasionally been reported
in patients with foetal alcohol syndrome (Reinhardt et al.,
2010). Finally, it remains possible that p.Asn674Ile (and
other polymicrogyria-associated GRIN1 mutations) may
have additional effects that have not been captured by
our electrophysiological analysis.
If polymicrogyria-associated GRIN1 mutations mainly
cause gain of function while non-polymicrogyria mutations
cause loss of function it raises the question why the two
types cause such similar phenotypes (severe developmental
delay, spasticity, early onset seizures, postnatal microceph-
aly, cerebral visual impairment and stereotypic movements).
A potential explanation is that gain-of-function mutations
may cause cell death (due to excitotoxicity) soon after neu-
rons begin expressing NMDA receptors. Early cell loss
would thin the foetal cortex (leading to polymicrogyria)
and result in a postnatal cortex depleted of cells expressing
NMDA receptors. In contrast, loss-of-function mutations
may cause cell death more gradually (e.g. due to loss of
NMDA-mediated pro-survival signalling) missing the key
window when polymicrogyria occurs (522 weeks). Having
cells in the postnatal cortex which are insensitive to glutam-
ate (due to loss-of-function mutations) may be functionally
equivalent to the cells being absent (due to gain-of-function
mutations). The evidence of cerebral atrophy observed in
several patients was present in infancy and progressed on
subsequent scans (Patient 11). The atrophy is likely due to
the direct effects of mutations (excitotoxicity or loss of pro-
survival signalling) as well as damage from frequent seizures.
In conclusion, we have found de novo GRIN1 missense
mutations in patients with extensive bilateral polymicro-
gyria. Our results provide evidence for a genotype–pheno-
type correlation with most polymicrogyria-associated
GRIN1 mutations clustering in the S2 or M3 domains,
regions of the protein rarely mutated in non-polymicrogyria
patients or the normal population. In addition, we showed
that polymicrogyria-associated GRIN1 mutations signiﬁ-
cantly alter in vitro NMDA receptor function. Our results
conﬁrm the importance of de novo mutations in the aeti-
ology of MCDs and polymicrogyria; expand the phenotypic
spectrum associated with GRIN1 mutations; demonstrate
similarities between human polymicrogyria and animal
models of the disorder; and highlight the important role
of NMDA signalling in the pathogenesis of polymicrogyria.
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